Post on 15-Oct-2015
5/25/2018 Rasionalisasi Obat Herbal.ppt
1/33
Rasionalisasi Penggunaan
Obat Herbal
Armen Muchtar
Departemen Farmakologi Klinik
RSUPN Dr Cipto Mangunkusumo
5/25/2018 Rasionalisasi Obat Herbal.ppt
2/33
Dampak Industri Terhadap
Pelayanan Kesehatan
Masalah Obat Modern.
Masalah Alat Kesehatan
Masalah Obat Herbal Konglomerasi Sarana/Komersialisasi
Pelayanan
5/25/2018 Rasionalisasi Obat Herbal.ppt
3/33
Latar Belakang Masalah Obat
Kemajuan teknologi/industri farmasi drugexplosiontherapeutic jungle.
Obat sebagai commodity dengan ciri
aggressive marketing: detailing, sponsorship,incentives, hidden curriculum, diseasemongering, multi-level marketing, direct toconsumers advertising, consumer supportingorganization, fraud, bribery, dll.
Industri farmasi kapitalistis: harga tak bolehdikontrol, serahkan ke pasar; diberlakukanmasa patent obat baru mahal.
5/25/2018 Rasionalisasi Obat Herbal.ppt
4/33
Improper Conduct of US
Pharmaceutical Industries
Inflated government reimbursement for prescriptiondrugs.
Kickbacks to private insurers for favoring drug onformularies.
Aggressively marketed drug for off-labeled indication. Kickbacks to high-prescribing physicians.
False statement about safety.
False statement about drug efficacy to induce
prescription writing. Holding continuing medical education meetings to induce
writing of un approved prescription.
Paid providers to induce prescription through paymentsfor training, consultation, or research.
5/25/2018 Rasionalisasi Obat Herbal.ppt
5/33
Predominance role of commercial rather than
scientific source of drug information represents
a problematic area in healthcare delivery. In
the absence of mandatory postgraduateeducation or recertification, pharmaceutical
advertising becomes the major source of
continuing medical education for physicians.
( Leighton Cluff), 1967)
5/25/2018 Rasionalisasi Obat Herbal.ppt
6/33
The House of Commons: Committee Report on
the Influence of Pharmaceutical Industry
The influence of pharmaceutical industryis enormous and out of control.
The big pharmas tentacles penetrate
much more widely, reaching patients,health departments, regulators,managers, researchers, medicalcharities, academics, media, cares,school children, and politicians.
( The Lancet, 2006)
5/25/2018 Rasionalisasi Obat Herbal.ppt
7/33
The excessive influence of industry willnot be curbed unless and until all thoseinvolved with drug companies take a
stand and question their relation withthem. Patients welfare will continue tobe vulnerable with health policies andpractices that are dominated by the will
of big pharmas.(The Lancet, 2006)
5/25/2018 Rasionalisasi Obat Herbal.ppt
8/33
Survai Masalah Penggunaan Obat
di Rumah Sakit
Those on medical wards of university hospitalreceived an average of 14 drugs during theirstay.
(Leighton Cluff, 1964)
Hospitalized patients received an average of15 drug administration per day.
( Mannase, 1989).
Serious adverse drug events occurred in about
6.7% of hospitalized patients, or more than100.000 deaths in US hospitals per year.
(Lazarou, 1998)
5/25/2018 Rasionalisasi Obat Herbal.ppt
9/33
Masalah Obat
Excessive use: overuse, abuse, misuse
Expensive: impoverishment/catastrophic
expenditure.
Harmful: fatal/severe adverse drug
events.
Too many: me-too drugs, copy drugs. Doubtful: placebo effect, marginal effect.
5/25/2018 Rasionalisasi Obat Herbal.ppt
10/33
Jalur Pemecahan Masalah Obat
Penelitian.
Pendidikan
Pelayanan. Kebijakan dan regulasi
Keprofesian
5/25/2018 Rasionalisasi Obat Herbal.ppt
11/33
Instrumen Pemecahan Masalah
Obat
Registrasi obat.
Konsep dan implementasi uji klinik
Konsep dan implementasi obat esensial
Monitoring efek samping obat
Konsep dan implementasi penggunaan obat
yang rasional.
Universal insurance coverage and managedcare
Substitusi generik dan substitusi terapeutik
5/25/2018 Rasionalisasi Obat Herbal.ppt
12/33
Hospital drug by-laws.
Ektensi disiplin ilmu: farmakologi klinik,epidemiologi klinik/farmakoepidemiologi,ekonomi kesehatan/farmakoekonomik, farmasi
klinik. Clinical trial registry, Consolidated Standards of
Reporting Trial Statements (CONSORT).
Critical appraisal, meta-analysis, evidence-
based pharmacotherapy, therapeutic guidelines. Health Technology Assessment/Comparative
Effectiveness Study.
Konsep dan implementasi Patient Safety
5/25/2018 Rasionalisasi Obat Herbal.ppt
13/33
Natural Products (NPs) in the World
Market
NP remedies are sold like pharmaceutical remedies;they are widely available for purchase frompharmacies, health-food stores, supermarkets, by mailorder, via the internet, and other retail outlets.
They are mostly produced by industrial/pharmaceuticalcompany, registered as food supplements, butmarketed as medicine.
They are aggressively marketed like conventionalmedicine.
Herbal products are the most widely available NPs.
5/25/2018 Rasionalisasi Obat Herbal.ppt
14/33
Regulation of NPs in UK
NPs are marketed as: 1) licensed NPs, 2) NPsexempting from licensing, 3) unlicensed NPs sold asfood supplements.
Many licensed NPs for minor self-limiting conditionsrely on bibliographic evidence to support efficacy andsafety.
NPs exempting from licensing are those compoundedand supplied by practitioners on their ownrecommendation, sold under their botanical name andwith no written recommendation for use.
NPs that are industrially produced are required to holdmarketing authorization.
Most NPs are sold as food supplement without makingmedical claim.
5/25/2018 Rasionalisasi Obat Herbal.ppt
15/33
Herbal Medicinal Products in
Germany
The use of plant drugs is an established
science. Herbal medicinal products known as
phytomedicine or phytotherapeutic agents are
prescribed in an evidence-based manner. Herbal medicinal products with documented
pharmacological activity and clinical efficacy
lie alongside conventional medicine. For
example, standardized senna preparation isclassified as conventional medicine.
5/25/2018 Rasionalisasi Obat Herbal.ppt
16/33
Herbal Medicine in US
Most herbal products in the US are considered dietarysupplements.
They are marketed without prior approval of their efficacy andsafety by FDA.
The manufacturer of an herbal preparation is responsible for thetruthfulness of claims made on the label and must have evidencethat the claims are supported, but it does not require submissionof the evidence to FDA.
Under 1994 Dietary Supplement and Health Education Act(DSHEA), the manufacturer is permitted to claim that the productaffects the structure or function of the body, as long as there is noclaim of effectiveness for the prevention or treatment of specific
disease. If a concern about safety arises, the burden of proof lies not with
the manufacturer but with the FDA, which has to prove that theproduct is unsafe.
5/25/2018 Rasionalisasi Obat Herbal.ppt
17/33
Problems of the Use of NPs
Conflicting outcome of efficacy and safety due toheterogeneity of active compounds, contentconcentration, and processing of raw materials.
Lack of/less validity in conducting clinical trials, so thatthe results are considered as not reliable.
Evidence of their quality, efficacy, and safety has notbeen thoroughly assessed as applied to conventionalmedicine.
Frequently enough, NPs are adulterated bymicroorganisms, toxins, pesticides, fumigation agents,or drugs.
The use of HM can pose serious adverse effects(cardiotoxicity, hepatotoxicity, neurotoxicity,hepatotoxicity, and drug interactions).
5/25/2018 Rasionalisasi Obat Herbal.ppt
18/33
Improved and unimproved BPH
treated with Saw Palmetto
3139 men from 21 RCTs lasting for 4-48 weeks wereassessed. 18 trials were double-blinded and treatmentallocation concealment was adequate in 11 studies.Compared with placebo, saw palmetto improvedurinary symptoms score, symptoms and flow measure
( Wilt et al, 2006) 225 men over 49 years who had a moderate to severe
symptoms of BPH were randomly assigned to oneyear of treatment with saw palmetto (2X160 mg) orplacebo. Saw palmetto did not improve symptoms or
objective measure of BPH ( Bent et al, 2006) This study raises the question about the variability of
botanical products; additional studies are needed toreach fix conclusion ( Peola et al, 2006)
5/25/2018 Rasionalisasi Obat Herbal.ppt
19/33
Instrument for the Critical Appraisal
of Trial of Herbal Medicine (HM)
1. The genus of test HM was stated.
2. The species of test HM was stated.
3. The plant part used to prepare the test HM wasstated.
4. How the test HM was processed/extracted wasdescribed.
5. If the test HM was a commercial product, the brandname was stated.
6. If the test HM was a commercial product, the name
of manufacturer was stated.7. If the test HM was a commercial product, the lot
number was stated.
8. The name of the important chemical(s) of the testHM was stated.
5/25/2018 Rasionalisasi Obat Herbal.ppt
20/33
9. The amount of important chemicals of the test HM
was stated.
10. The test HM was analyzed for chemical content.
11. The dosage form of the test HM was stated.
12. The dose of the test HM was stated.13. The frequency of administration of the test HM was
stated.
14. The route of administration of the test HM was stated.
15. The placebo or comparison treatment and the testHM were matched in terms of taste, smell,
appearance, and dosing regimen.
16. The success of blinding was evaluated.
5/25/2018 Rasionalisasi Obat Herbal.ppt
21/33
Proposed Research Strategy for HM
Folk experience of HM
hint or clue pharmaceutical study in GAP and CMPStandardized pure compounds
In vitro & in vivo pharmaco-toxicological study
Findings published in refereed journals
CTs performed in GCP, Cochrane ReviewsProved by EBM
New Application
New drugs
5/25/2018 Rasionalisasi Obat Herbal.ppt
22/33
Chinese Herbal Medicine as a
resource of liver fibrosis treatment
Research has gone through three stages: 1)clinical exploration, 1950s-1970s; 2)experimental investigation (1970s-1990s); 3)clinical trials and molecular studies (1990s
onward). Action mechanisms: inhibition of viral
replication, immunomodulation, anti-oxidationand anti-inflammation, inhibition of fibrogenicprocess.
Efficacy: reverse liver fibrosis in CHB, reducesDNA replication of HBV, lowers serum ALT,reduces the incidence of HCC.
5/25/2018 Rasionalisasi Obat Herbal.ppt
23/33
Safety: interstitial pneumonitis, fatal biliarycirrhosis, hepatic veno-occlusive disease.
Evidence against: two reviews did not
recommends the use of herbal medicine totreat chronic liver disease.
Conclusion: Strict quality control is critical forpharmacological, clinical, and in-depth studies.
Experiments and clinical trials should becarried out on the platforms that conform tointernational standards.
5/25/2018 Rasionalisasi Obat Herbal.ppt
24/33
Systematic reviews have found that
many clinical trials testing
complementary or alternative medicine
have major flaws, such as insufficientstatistical power, poor controls,
inconsistency of treatment or product,
and lack of comparison with othertreatments, with placebo, or with both.
5/25/2018 Rasionalisasi Obat Herbal.ppt
25/33
Finding appropriate placebos or shams for
treatment such as acupuncture, chiropractic,
message therapy, or complex herbal mixture is
challenging. Complementary and alternative treatments
typically involved extended and intensive
interaction between the patient and the
practitioner, which greatly increase thepossibility of a placebo effect..
5/25/2018 Rasionalisasi Obat Herbal.ppt
26/33
Various Expectation Effects Behind
the Placebo Response
Hawthorne effect: subjects respond to knowledgebeing evaluated or observed,
Jastrow effect: subjects respond to explicitexpectation about outcome.
Pygmalion effect: evaluator expect therapeuticbenefit so they see it.
John Henry effect: subjects tend to emulate expectedoutcomes
Halo effect: subjects respond to treatment novelty.
Experimenter effect: evaluator interpreted outcomedifferently.
Socialization effect: other reporting apparent effectinfluence the outcome.
Value effect: costs influence expected outcome.
5/25/2018 Rasionalisasi Obat Herbal.ppt
27/33
Integrative vs Conventional
Medicine
Andrew Weil MD: Clearly there is adissatisfaction with conventional medicine.
I consider experience to be one of valuablesource of datain my experience, many
patients use alternative methods because theywork. .. Large numbers of patient havefound that there are treatment out of there thattheir conventional medicine physicians do notknow about, did not advise them about, thathave worked for them in some cases afterconventional medicine has failed.
5/25/2018 Rasionalisasi Obat Herbal.ppt
28/33
A.S Relman MD: Future in clinical practice willdepend on the application of new development inscience, biotechnology, molecular pharmacology, andthe use of clinical epidemiology based on analysis of
objective clinical data. We need to see manymore controlled studies comparing standardizedherbal preparation with conventional pharmaceuticalbefore concluding that herbs have any specialadvantage over conventional drugs and that herbal
therapy should be taught in medical schools.
(Arch Intern Med 1999;159:2122-2126)
5/25/2018 Rasionalisasi Obat Herbal.ppt
29/33
At present, integrative medicine is largely
market-driven and spans the spectrum
from evidence-based practices that
benefit patients and carry little risk tooutright quackery, sometimes with
significant risk
5/25/2018 Rasionalisasi Obat Herbal.ppt
30/33
Penyelengaraan Pengobatan Komplementer
Alternatif di Fasilitas Pelayanan Kesehatan
Pelaksana pengobatan komplementer-
alternatif adalah dr/drg, serta tenaga
kesehatan lainnya yang teregistrasi dan
memiliki surat tugas/SIK-TPKA sesuaiketentuan berlaku, memiliki sertifikat
kompetensi sesuai bidang keahliannya,
dan mendapat rekomendasi dariorganisasi profesi terkait.
5/25/2018 Rasionalisasi Obat Herbal.ppt
31/33
Standard Pelayanan Medik Herbal
Standard Kompetensi: adalah kemampuanminimal yang harus dimiliki oleh doktermeliputi pengetahuan, keterampilan danperilaku, untuk dapat melakukan pekerjaan
secara efektif dalam bidang herbal, danmendapat sertifikasi dari KolegiumFarmakologi Klinik.
Dokter harus memperoleh rekomendasi dariPerhimpunan Pengembang KesehatanTradisional Timur (PDPKT) sebagai organisasiseminat dibawah IDI, dan drg dari organisasiprofesinya.
5/25/2018 Rasionalisasi Obat Herbal.ppt
32/33
BPOM telah mengeluarkan registrasi 24 obat
herbal terstandar dan 5 jenis fitofarmaka.
PDPKTI berhasil memilih 30 jenis tanaman
berkhasiat dalam mengatasi berbagai macampenyakit.
Perlu suatu pelayanan medik herbal yang
berkualitas dan pelaksanaannya sesuai etika
kedokteran dengan prinsip manfaat dan
keamanan yang didasarkan pada pembuktian.
5/25/2018 Rasionalisasi Obat Herbal.ppt
33/33